A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis

The New England Journal of Medicine
Ayalew TefferiAnimesh Pardanani

Abstract

Current drugs for myeloproliferative neoplasm-associated myelofibrosis, including Janus kinase (JAK) inhibitors, do not induce complete or partial remissions. Imetelstat is a 13-mer lipid-conjugated oligonucleotide that targets the RNA template of human telomerase reverse transcriptase. We sought to obtain preliminary information on the therapeutic activity and safety of imetelstat in patients with high-risk or intermediate-2-risk myelofibrosis. Imetelstat was administered as a 2-hour intravenous infusion (starting dose, 9.4 mg per kilogram of body weight) every 1 to 3 weeks. The primary end point was the overall response rate, and the secondary end points were adverse events, spleen response, and independence from red-cell transfusions. A total of 33 patients (median age, 67 years) met the eligibility criteria; 48% had received prior JAK inhibitor therapy. A complete or partial remission occurred in 7 patients (21%), with a median duration of response of 18 months (range, 13 to 20+) for complete responses and 10 months (range, 7 to 10+) for partial responses. Bone marrow fibrosis was reversed in all 4 patients who had a complete response, and a molecular response occurred in 3 of the 4 patients. Response rates were 27% among p...Continue Reading

References

May 31, 1990·Nature·C B HarleyC W Greider
Aug 30, 1990·Nature·N D HastieR C Allshire
Sep 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·R K MoyzisJ R Wu
Aug 24, 1999·Cell·T de Lange, T Jacks
Oct 7, 2006·Nature Medicine·Elizabeth H BlackburnJack W Szostak
Dec 5, 2008·Nature·Jessica A BoxPeter Baumann
Aug 25, 2009·Nature·Yoshiko MaidaKenkichi Masutomi
Jan 15, 2010·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·Alexander RöthGabriela M Baerlocher
Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naseema GangatAyalew Tefferi
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Animesh PardananiAyalew Tefferi
Feb 22, 2011·Journal of Cellular and Molecular Medicine·Michel M OuelletteJerry W Shay
Mar 2, 2012·The New England Journal of Medicine·Claire HarrisonGiovanni Barosi
Mar 2, 2012·The New England Journal of Medicine·Srdan VerstovsekHagop M Kantarjian
Nov 20, 2012·Nature Cell Biology·Arkasubhra GhoshVinay Tergaonkar
Apr 27, 2013·Leukemia·A M VannucchiA Tefferi
Jul 17, 2015·JAMA Oncology·Ayalew Tefferi, Animesh Pardanani

❮ Previous
Next ❯

Citations

Oct 23, 2015·American Journal of Hematology·Ayalew Tefferi
Dec 25, 2015·The New England Journal of Medicine·Gabriela M BaerlocherDavid S Snyder
Sep 29, 2015·Current Hematologic Malignancy Reports·Naveen PemmarajuMichael A Thompson
Aug 19, 2015·Current Hematologic Malignancy Reports·Giovanni Barosi
Apr 28, 2016·Pharmacology & Therapeutics·Yinnan Chen, Yanmin Zhang
Jun 1, 2016·Leukemia & Lymphoma·Tariq I MughalRichard A Van Etten
Jun 25, 2016·Nature Reviews. Cancer·Greg M Arndt, Karen L MacKenzie
May 31, 2016·Genes·Yucheng Xu, Amir Goldkorn
Jul 11, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Karima Ait-AissaAndreas M Beyer
Oct 28, 2016·British Journal of Haematology·Xin ZhaoSawa Ito
Aug 9, 2016·Bulletin du cancer·Juliette Soret, Jean-Jacques Kiladjian
Aug 16, 2016·Clinical Lymphoma, Myeloma & Leukemia·Thomas Prebet, Amer Zeidan
Aug 12, 2016·Hematological Oncology·Francesca PalandriMichele Baccarani
Aug 20, 2016·Annals of Hematology·Lindsey ShantzerJeffrey J Pu
Aug 19, 2016·Genes·Theresa KreilmeierKlaus Holzmann
Sep 23, 2016·European Journal of Medicinal Chemistry·Philip A WaghornKatherine A Vallis
Sep 20, 2016·Journal of the American Chemical Society·Hyun-Jin KangLaurence H Hurley
Oct 8, 2016·Blood Cancer Journal·G CaocciG La Nasa
Nov 2, 2016·Expert Opinion on Investigational Drugs·Prithviraj Bose, Srdan Verstovsek
Nov 25, 2016·Expert Review of Hematology·Guido Lancman, John Mascarenhas
Dec 29, 2016·Blood·Alessandro M Vannucchi, Claire N Harrison
Mar 10, 2017·Expert Review of Hematology·Maximilian Stahl, Amer M Zeidan
Apr 12, 2017·Expert Review of Hematology·Maximilian Stahl, Amer M Zeidan
Mar 16, 2017·Journal of Cellular Physiology·Ciprian TomuleasaStefan O Ciurea
Jan 11, 2017·Current Opinion in Hematology·Rita AssiNaval Daver
Feb 27, 2018·Expert Opinion on Emerging Drugs·Aditya Shreenivas, John Mascarenhas
Nov 17, 2017·International Journal of Molecular Sciences·Theresa VaskoPatrick Ziegler
Mar 9, 2018·Expert Review of Hematology·Patrick M Harrington, Claire N Harrison
Feb 9, 2018·International Journal of Molecular Sciences·Takahiro EitsukaTeruo Miyazawa
Dec 15, 2017·Nucleic Acids Research·Xiulong Shen, David R Corey
Nov 3, 2017·Therapeutic Advances in Hematology·Ashwin Kishtagari, Justin Watts
Nov 4, 2017·Current Hematologic Malignancy Reports·Kristen Pettit, Olatoyosi Odenike
Dec 16, 2017·Blood Cancer Journal·Ayalew Tefferi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.